DGCI gives emergency approval of DRDO-developed anti-Covid oral drug | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Saturday
July 12, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
SATURDAY, JULY 12, 2025
DGCI gives emergency approval of DRDO-developed anti-Covid oral drug

Coronavirus chronicle

Hindustan Times
08 May, 2021, 02:25 pm
Last modified: 08 May, 2021, 02:28 pm

Related News

  • India showcases naval ballistic missile defence capability in maiden test
  • Beximco to produce Pfizer’s Covid-19 drug locally 
  • Beximco Pharma gets license for oral anti-Covid drug
  • Incepta launches Pfizer’s anti-Covid pill
  • WHO-led program aims to buy antiviral Covid-19 pills for $10

DGCI gives emergency approval of DRDO-developed anti-Covid oral drug

The oral drug has been developed by Institute of Nuclear Medicine and Allied Sciences, a lab of DRDO, in collaboration with Dr Reddy’s Laboratories, Hyderabad. Phase III clinical trial results have shown that this molecule helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence

Hindustan Times
08 May, 2021, 02:25 pm
Last modified: 08 May, 2021, 02:28 pm
Indian Prime Minister Narendra Modi. Photo: NDTV
Indian Prime Minister Narendra Modi. Photo: NDTV

An anti-Covid-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddy's Laboratories, Hyderabad. Clinical trial results have shown that this molecule helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in Covid patients. The drug will be of immense benefit to the people suffering from Covid in the ongoing pandemic.

Pursuing the Hon'ble Prime Minister's call for preparedness against the pandemic, DRDO took the initiative of developing anti-Covid therapeutic application of 2-DG. In April 2020, during the first wave of pandemic INMAS-DRDO scientists conducted laboratory experiments with the help of Centre for Cellular and Molecular Biology (CCMB), Hyderabad and found that this molecule works effectively against SARS-CoV-2 virus and inhibits the viral growth. Based on these results, Drugs Controller General of India's (DCGI) Central Drugs Standard Control Organization (CDSCO) permitted Phase-II clinical trial of 2-DG in Covid-19 patients in May 2020.

DRDO along with its industry partner Dr Reddy's Laboratories (DRL, Hyderabad) started the clinical trials to test the safety and efficacy of the drug in Covid-19 patients. In Phase-II trials (including dose ranging) conducted during May to October 2020, the drug was found to be safe in Covid-19 patients, and showed significant improvement in their recovery. Phase IIa was conducted in 6 hospitals and Phase IIb (dose ranging) clinical trial was conducted at 11 hospitals all over the country. Phase-II trial was conducted on 110 patients. In efficacy trends, the patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints. A significantly favourable trend (2.5 days difference) was seen in terms of the median time to achieving normalization of specific vital signs parameters when compared to SOC.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Top News / World+Biz

DGCI / Defence Research and Development Organisation (DRDO) / Covid oral drug / oral drug

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Bangladesh and US hold tariff talks on 11 July 2025. Photo: CA Press Wing
    Two countries yet to agree on 20% of US tariff conditions: BGMEA
  • RAB Director General AKM Shahidur Rahman speaks at the press briefing on a fake bomb threat on Biman Bangladesh flight on Saturday, 12 July 2025. Photo: TBS
    Mother faked bomb threat on Biman flight to stop married son from flying to Kathmandu with girlfriend: RAB
  • Jubo Dal President Abdul Monayem Munna and other leaders of BNP's affiliate wings at a press conference at Nayapaltan office in Dhaka on Saturday. Photo: TBS
    Mitford murder: Jubo Dal accuses police of intentional neglect, demands arrest of ‘3 real killers’

MOST VIEWED

  • Representational image
    In addition to 35% tariff, US demands 40% local value addition for 'Made in Bangladesh' goods
  • Screengrab blurred
    Killers bash in head of man with rock, stomp body with perverse pleasure
  • How tender rules and a lone bidder stall a $2.5b power plant
    How tender rules and a lone bidder stall a $2.5b power plant
  • Economist Abul Barkat; Photo: Courtesy
    Economist Abul Barkat arrested in graft case
  • Photo: UNB
    WHO's Saima Wazed Putul 'placed on indefinite leave' amid corruption allegations: Health Policy Watch
  • After India's visa restriction, China's Kunming is drawing Bangladeshi patients
    After India's visa restriction, China's Kunming is drawing Bangladeshi patients

Related News

  • India showcases naval ballistic missile defence capability in maiden test
  • Beximco to produce Pfizer’s Covid-19 drug locally 
  • Beximco Pharma gets license for oral anti-Covid drug
  • Incepta launches Pfizer’s anti-Covid pill
  • WHO-led program aims to buy antiviral Covid-19 pills for $10

Features

After India's visa restriction, China's Kunming is drawing Bangladeshi patients

After India's visa restriction, China's Kunming is drawing Bangladeshi patients

20h | Panorama
Photo: Collected/BBC

What Hitler’s tariff policy misfire can teach the modern world

1d | The Big Picture
Illustration: TBS

Behind closed doors: Why women in Bangladesh stay in abusive marriages

1d | Panorama
Purbachl’s 144-acre Sal forest is an essential part of the area’s biodiversity. Within it, 128 species of plants and 74 species of animals — many of them endangered — have been identified. Photo: Syed Zakir Hossain/TBS

A forest saved: Inside the restoration of Purbachal's last Sal grove

1d | Panorama

More Videos from TBS

Home Affairs Advisor calls on everyone to come forward and stop violence

Home Affairs Advisor calls on everyone to come forward and stop violence

1h | TBS Today
More than a thousand layoffs at once in US government agencies

More than a thousand layoffs at once in US government agencies

2h | TBS World
Bangladesh-US tariff talks unresolved

Bangladesh-US tariff talks unresolved

3h | TBS Stories
Putul on indefinite leave after four months in 2 ACC cases

Putul on indefinite leave after four months in 2 ACC cases

3h | TBS Stories
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net